About IRIS International, Inc.
IRIS International is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 2,300 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and urinary tract infections. In addition, the Company is developing molecular diagnostic tests based on its Nucleic Acid Detection Immunoassay, or NADiA(r), platform, with applications in oncology and infectious disease. For more information visit www.proiris.com.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: IRIS International, Inc.
IRIS International, Inc. Cesar Garcia, Chairman and Chief Executive Officer 818-709-1244, x 7123 The Wall Street Group, Inc. Ron Stabiner 212-888-4848

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index